EU drug agency flags CBD market issues in report on low-THC cannabis products

The European Union’s drug agency has signaled that it is mulling the legal and commercial status of CBD and cannabis-based products in Europe in a new report.

The Lisbon-based European Monitoring Centre for Drugs and Drug Addiction published the report on Monday, detailing the results of a study that kicked off in 2018 and aimed to provide insight into the open sale of low-THC products in Europe.

“The specific objectives were to identify and further explore the types of product available and the range of sales outlets, user profiles, associated harms and responses taken in different EU countries,” the authors wrote.

The Centre took note of several glaring issues with the marketing and promotion of some CBD products across Europe, including:

for more

Handbook CannabisPathologies